PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel, F-18 fluoropaclitaxel (FPAC), may be able to predict the uptake of paclitaxel in solid tumors, and as a substrate of P-glycoprotein, it may also predict which tumors exhibit multidrug resistance (MDR), a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic, preclinical and early human data obtained during the development phase of this promising new radiopharmaceutical.
Kurdziel
Karen A
KA
Molecular Imaging Program/CCR, National Cancer Institute, 10/B3B403, 10 Center Drive MSC 1180, Bethesda, MD 20892, USA. kurdziek@mail.nih.gov
Kiesewetter
D O
DO
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005462:Fluorine Radioisotopes / Q000737:chemistry; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry; D049268:Positron-Emission Tomography
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D005462:Fluorine Radioisotopes; C526531:4-fluoropaclitaxel; D017239:Paclitaxel